Grey Wolf Therapeutics
Biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer neoantigen creation
Oxford, UKgreywolftherapeutics.com ↗
Total raised
€88M
€87,538,549
Funding rounds
2
Investors
7
distinct backers
Active since
2023-01
latest 2024-05
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood52
base rate 48% for Series B
- ▲ In typical raise window
- ▼ Low backer re-investment
Exit likelihood14
base rate 12% (2+ rounds)
- ▲ €30M+ raised
Timing: in window vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-05-23 | Series B | €42M | Andera Partners,British Patient Capital,Canaan,Earlybird Venture Capital,ICG’s Life Sciences,Oxford Science Enterprises+1 more | View deal → |
| 2023-01-26 | Series B | €45M | Andera Partners,British Patient Capital,Canaan,Earlybird Venture Capital,Oxford Science Enterprises,Pfizer Ventures | View deal → |
Investors
7Related news
- Grey Wolf Therapeutics Closes $49M Series B Financingfinsmes.com · 2023-01
- eu-startups.com